Salix settles MoviPrep patent dispute with Novel

RALEIGH, N.C. Salix Pharmaceuticals announced its agreement with Novel Labs to settle its patent litigation over Novel’s proposed generic version of MoviPrep.

Pending approval by the court, Salix, Norgine B.V. and Novel have agreed to a consent judgment that will result in the dismissal of all claims in the litigation, which currently is pending in the U.S. District Court for the District of New Jersey. The settlement includes a sublicense agreement pursuant to which Salix and Norgine have granted Novel a license to the patents covering MoviPrep effective no later than Sept. 24, 2018. Under the terms of a separate supply agreement, Novel will manufacture and supply MoviPrep to Salix, providing Salix with a domestic supply source.

MoviPrep (polyethylene glycol) is a prescription medicine that is given to colonoscopy patients prior to the procedure.